Gyre Therapeutics (GYRE) Projected to Post Earnings on Tuesday

Gyre Therapeutics (NASDAQ:GYRE) will likely be announcing its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $23.50 million for the quarter.

Gyre Therapeutics Price Performance

Shares of NASDAQ GYRE opened at $12.28 on Tuesday. Gyre Therapeutics has a 12-month low of $8.26 and a 12-month high of $19.00. The company’s fifty day simple moving average is $11.32 and its 200 day simple moving average is $12.29.

Wall Street Analyst Weigh In

Separately, Noble Financial assumed coverage on shares of Gyre Therapeutics in a research note on Tuesday, March 11th. They set an “outperform” rating on the stock.

Insider Buying and Selling at Gyre Therapeutics

In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the transaction, the president now directly owns 2,928,467 shares of the company’s stock, valued at approximately $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 36,054 shares of company stock valued at $409,057. Corporate insiders own 19.52% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Gyre Therapeutics stock. Bank of America Corp DE grew its position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 40.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,937 shares of the company’s stock after purchasing an additional 1,996 shares during the period. Bank of America Corp DE’s holdings in Gyre Therapeutics were worth $84,000 at the end of the most recent reporting period. 23.99% of the stock is currently owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.